Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?

Selma Addou, Clémentine Sarkozy, Julien Lazarovici, Stéphane Champiat, Aspasia Stamatoullas, Fabrice Jardin, Vincent Ribrag, Aurélien Marabelle, Jean Marie Michot

    Résultats de recherche: Contribution à un journalArticle 'review'Revue par des pairs

    Résumé

    Classical Hodgkin lymphoma is a neoplastic hematological disease. Standard first-line therapy, including chemotherapy and radiotherapy, is curative in >85% of early-stage patients, with a 5-year survival rate of >95%. However, approximately 15% of patients have hard-to-treat lymphoma with poor outcomes, and new treatment strategies are needed for these young adults. There are several well-documented cases in the medical literature on hematologic cancer remission following natural human viral infections. Therefore, hoping to reproduce these spontaneous tumor regressions, researchers have been investigating various viruses with oncolytic properties. There is a high rationale for using virotherapy in the treatment of Hodgkin lymphoma, in which tumor cells are often infected with the Epstein-Barr virus. Modern viral technologies and current knowledge about the relationship between viruses and cancer could accelerate the discovery of effective viral oncolytic therapies. This article reviews the use of oncolytic viruses as innovative therapies for treating Hodgkin lymphoma.

    langue originaleAnglais
    Pages (de - à)3502-3510
    Nombre de pages9
    journalHuman Vaccines and Immunotherapeutics
    Volume17
    Numéro de publication10
    Les DOIs
    étatPublié - 1 janv. 2021

    Contient cette citation